Pilosinine

Pilosinine

SCHEMBL8303826

Cn1cncc1C[C@H]1COC(=O)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 4/20 1.00
CHRM4 P08173 3/20 0.59
CHRM1 P11229 3/20 0.59
CHRM3 P20309 3/20 0.59
LMNA P02545 3/20 0.59
CYP3A4 P08684 3/20 0.59
CYP2C9 P11712 2/20 0.59
CHRM2 P08172 2/20 0.59
CYP2A6 P11509 1/20 0.59
CNR1 P21554 1/20 0.59
HTR2A P28223 1/20 0.59
CYP2A13 Q16696 1/20 0.59
MEN1 O00255 1/20 0.59
USP2 O75604 1/20 0.59
TP53 P04637 1/20 0.59
CYP1A2 P05177 1/20 0.59
ALOX15 P16050 1/20 0.59
ALOX12 P18054 1/20 0.59
NFKB1 P19838 1/20 0.59
MAPK1 P28482 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1509566 0.75 LMNA (0.81) CHRM5CHRM4CHRM1CHRM3LMNA
Pilocarpine SCHEMBL3078492 0.74 LMNA (1.00) CHRM5CHRM4CHRM1CHRM3LMNA
Pilocarpine SCHEMBL188019 0.74 LMNA (1.00) CHRM5CHRM4CHRM1CHRM3LMNA
Pilocarpine SCHEMBL41890 0.74 LMNA (1.00) CHRM5CHRM4CHRM1CHRM3LMNA
Pilocarpine SCHEMBL678045 0.74 LMNA (1.00) CHRM5CHRM4CHRM1CHRM3LMNA
Pilocarpine SCHEMBL9213198 0.74 LMNA (1.00) CHRM5CHRM4CHRM1CHRM3LMNA
Pilocarpine SCHEMBL15146 0.74 LMNA (1.00) CHRM5CHRM4CHRM1CHRM3LMNA
SCHEMBL10385161 0.73 CHRM5 (0.58) CHRM5CHRM4CHRM1CHRM3LMNA
Pilocarpine SCHEMBL7076217 0.73 LMNA (1.00) CHRM5CHRM4CHRM1CHRM3LMNA
Pilocarpine SCHEMBL725541 0.73 LMNA (1.00) CHRM5CHRM4CHRM1CHRM3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0486806-B1 Process for the preparation of racemic pilosinine derivatives MERCK PATENT GMBH (DE) 1996-01-17 EP claimed
JP-5059044-A None JP disclosed
JP-5059044-A None JP disclosed
EP-4644366-A1 PREPARATION METHODS FOR PILOCARPINE AND INTERMEDIATE COMPOUND THEREOF Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) 2025-11-05 EP disclosed
CN-116199607-B Preparation method of pilocarpine and intermediate compound thereof 浙江奥翔药业股份有限公司 2025-02-14 CN disclosed
US-20240228425-A1 PREPARATION METHOD OF PILOCARPINE AND ITS INTERMEDIATE COMPOUNDS ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) 2024-07-11 US disclosed
WO-2024140282-A1 PREPARATION METHODS FOR PILOCARPINE AND INTERMEDIATE COMPOUND THEREOF 浙江奥翔药业股份有限公司 2024-07-04 WO disclosed
WO-2019150341-A1 COMBINATION OF AN ANTIMUSCARINIC OR AN ANTICHOLINERGIC AGENT AND LIPOIC ACID AND USES THEREOF CELLIXBIO PRIVATE LIMITED (IN) 2019-08-08 WO disclosed
EP-0647640-B1 Process for the preparation of pilocarpine derivatives MERCK PATENT GMBH (DE) 1999-03-24 EP disclosed
US-5530136-A HIGH YIELD; BY-PRODUCT INHIBITION MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1996-06-25 US disclosed
EP-0486806-B1 Process for the preparation of racemic pilosinine derivatives MERCK PATENT GMBH (DE) 1996-01-17 EP disclosed
EP-0647640-A1 Process for the preparation of pilocarpine derivatives MERCK PATENT GmbH (DE) 1995-04-12 EP disclosed
JP-H0559044-A PREPARATION OF RACEMIC PILOSININE DERIVATIVE MERCK PATENT GMBH 1993-03-09 JP disclosed
JP-H0559044-A PREPARATION OF RACEMIC PILOSININE DERIVATIVE MERCK PATENT GMBH 1993-03-09 JP disclosed
US-5180837-A PILOSININE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1993-01-19 US disclosed
US-5180837-A PILOSININE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1993-01-19 US disclosed
US-5180837-A PILOSININE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 1993-01-19 US disclosed
EP-0486806-A1 Process for the preparation of racemic pilosinine derivatives MERCK PATENT GmbH (DE) 1992-05-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240228425-A1 PREPARATION METHOD OF PILOCARPINE AND ITS INTERMEDIATE COMPOUNDS CYP4B1, CYP4A11, CYP3A4 CHRM5 534/4885CHRM4 426/4885CHRM1 509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.